Vol.27/No.4

PMD-026 inhibits RSK to block tumor growth signals and ER activity, a potential strategy to overcome CDK4/6 inhibitor resistance in breast cancer.

PD-L1 expression may signal worse outcomes with frontline osimertinib in EGFR-mutant metastatic NSCLC, highlighting potential prognostic value.

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study evaluating the MET-directed ADC Temab-A vs SOC active surveillance in postadjuvant, ctDNA-positive CRC.

Data from KEYNOTE-B96 supported the first FDA approval of an immunotherapy regimen in PD-L1–positive platinum-resistant, recurrent ovarian cancer.

In a recent Peer Exchange, experts discussed RCC management and treatment sequencing considerations ahead of ASCO GU 2026.

Disrupting liver-driven immune sink by depleting macrophages and preventing T-cell clearance restores responsiveness to immunotherapy in melanoma.

Maurie Markman, MD, discusses ethical dilemmas in oncology trials, balancing patient welfare with research integrity and regulatory goals.

A group of researchers from the University of Miami sought to understand why many clinical trials in head and neck cancers fail.

Experts break down the FDA’s draft guidance on the use of MRD end points to support accelerated drug approvals in multiple myeloma.